FY2025 · ended Dec 31, 2025 · Revenue $0, -100.0% YoY · Filed Mar 26, 2026
Zentalis Pharmaceuticals, Inc. (ZNTL) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $137.1 million. Free cash flow was -$125.2 million. As of Jun 30, 2026 it held $174.6 million in cash and investments and $37.7 million in total debt.
Revenue
$0
-100.0% vs prior year
Net income
$-137.06M
+17.4% vs prior year
Operating cash flow (TTM)
$-128.09M
+15.2% vs year-ago TTM
Free cash flow (TTM)
$-128.13M
+15.2% vs year-ago TTM
EPS
$-1.91
+18.0% vs prior year
Dividend per share
None
Shares outstanding
70.93M
-1.2% vs prior year
Net cash
$136.92M
as of Jun 30, 2026
Operating margin
-283.6%
FY 2024
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZNTL (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1725160
- Former names
- Zentalis Pharmaceuticals, LLC (until Apr 6, 2020); Zeno Pharma, LLC (until Sep 5, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $67.4M | — | — | — |
| Operating income | -$152.8M | -$191.2M | -$299.5M | -$227.3M | -$216.5M |
| Net income | -$137.1M | -$165.8M | -$292.2M | -$236.8M | -$158.7M |
| Diluted EPS | -$1.91 | -$2.33 | -$4.47 | -$4.48 | -$3.72 |
| Operating cash flow | -$125.2M | -$170.9M | -$207.8M | -$163.8M | -$154.1M |
| Free cash flow | -$125.2M | -$171.1M | -$208.4M | -$166.3M | -$160.2M |
| Total assets | $289.0M | $430.3M | $551.7M | $539.3M | $454.5M |
| Total liabilities | $72.8M | $93.2M | $114.3M | $105.3M | $90.0M |
| Stockholders' equity | $216.2M | $337.2M | $437.3M | — | — |
| Cash and investments | $245.9M | $351.9M | $482.9M | $437.4M | $339.9M |
| Total debt | $39.6M | $42.6M | $45.8M | $47.3M | $45.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Aug 14, 2026 | Aug 13, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Officer or director change
|
May 27, 2026 | May 22, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
May 21, 2026 | May 21, 2026 |
All 546 Zentalis Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.